Skip to main content
Have a personal or library account? Click to login
The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer Cover

The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer

Radiology and Oncology
Volume 47 (2013): Issue 2 (June 2013)
By: ,  ,  ,   and    
Open Access
|May 2013
References

References

  1. 1. Kim DY, Jung KH, Kim TH, Kim DW, Chang HJ, Jeong JY, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.2007;378-84.
    Open DOISearch in Google Scholar
  2. 2. Chan AK, Wong AO, Jenken DA. Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer-is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?2010;1413-9.
    Search in Google Scholar
  3. 3. Velenik V, Ocvirk J, Oblak I, Anderluh F. Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial.2012;252-7.
    Open DOISearch in Google Scholar
  4. 4. Pesta M, Topolcan O, Holubec L Jr, Rupert K, Cerna M, Holubec LS, et al. Clinicopathological assesment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.2007;1863-7.
    Search in Google Scholar
  5. 5. Li M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metaloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth and angiogenesis.2006;20-7.
    Open DOISearch in Google Scholar
  6. 6. Giaginis C, Nikiteas N, Margeli A, Tzanakis N, Rallis G, Kouraklis G, et al. Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: association with clinicopathological variables and patients survival.2009;245-52.
    Open DOISearch in Google Scholar
  7. 7. Alo-Aho R, Kahari VM: Colagenases in cancer.2005;273-86.
    Search in Google Scholar
  8. 8. Sørensen NM, Sørensen IV, Wűrtz SØ, Schrohl AS, Dowell B, Davis G, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.2008;774-86.
    Open DOISearch in Google Scholar
  9. 9. Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, et al. Assesment of the biological variation of plasma tissue inhibitor of metalloproteinase-1.2008;42-7.
    Open DOISearch in Google Scholar
  10. 10. Wass ET, Hendriks T, Lomme RM, Woblles T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients.2005;700-10.
    Open DOISearch in Google Scholar
  11. 11. Kahlert C, Bandapalli OR, Schirmacher P, Weitz J, Brand K. Invasion frontspecific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.2008;1459-66.
    Search in Google Scholar
  12. 12. Oblak I, Anderluh F, Velenik V, Mozina B, Ocvirk J, Ciric E, et al. Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II-III.2011;209-12.
    Open DOISearch in Google Scholar
  13. 13. Sørensen NM, Byström P, Christensen IJ, Berglund A, Nielsen HJ, Brüner N, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients reciving combination of irinotecan, 5-fluorouracil, and folinic acid.2007;4117-22.
    Open DOISearch in Google Scholar
  14. 14. Unsal D, Under A, Akyurek N, Erpolat P, Dursun A, Pak Y. Matrix metalloproteinase-9 expression correlates with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy.2007;196-203.
    Open DOISearch in Google Scholar
  15. 15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.1958;457-81.
    Open DOISearch in Google Scholar
  16. 16. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples.1977;1-39.
    Open DOISearch in Google Scholar
  17. 17. Cox DR. Regression models and life-tables.1972;187-220.
    Open DOISearch in Google Scholar
  18. 18. Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brűner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.2006;1886-96.
    Open DOISearch in Google Scholar
  19. 19. Yakawa N, Yoshikawa T, Akaike M, Sugimasa Y, Rino Y, Masuda M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on longterm survival in patients with colorectal cancer.2007;205-8.
    Open DOISearch in Google Scholar
  20. 20. Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.2010; 5: 88-96.
    Open DOISearch in Google Scholar
  21. 21. Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, et al. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.2008;450-6.
    Open DOISearch in Google Scholar
  22. 22. Holten-Anderson MN, Christensen IJ, Nielsen HJ, Lilja H, Murphy G, Jensen V, et al. Measurement of the non-complex free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay.2002;1305-13.
    Open DOISearch in Google Scholar
  23. 23. Holten-Anderson M, Christensen IJ, Nilberg M, Bendahl PO, Nielsen HJ, Brűnner N, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study.2004;64-72.
    Open DOISearch in Google Scholar
  24. 24. Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP- 1) in colorectal cancer patients.2003;885-92.
    Open DOISearch in Google Scholar
  25. 25. Tayebjee MH, Lip GYH, Blann AD, MacFadyen RJ. Effects of age, gender, ethnicity, diurnal variations and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and-9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.2005;205-10.
    Open DOISearch in Google Scholar
  26. 26. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.2003;718-27.
    Open DOISearch in Google Scholar
  27. 27. Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, et al. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?2010;27
    Search in Google Scholar
  28. 28. Laohavinij S, Maneechavakaiorn J, Techatanol P. Prognostic factors for survival in colorectal cancer patients.2010;1156-66.
    Search in Google Scholar
DOI: https://doi.org/10.2478/raon-2013-0028 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 138 - 144
Published on: May 21, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
tissue inhibitor of metalloproteinases,
rectal cancer,
preoperative radiochemotherapy,
prognostic factors
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2013 Irena Oblak, Vaneja Velenik, Franc Anderluh, Barbara Mozina, Janja Ocvirk, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 47 (2013): Issue 2 (June 2013)
Previous article
Next article